does ozempic work better than semaglutide

does ozempic work better than semaglutide Ozempic® Pen vs Other Type 2 Diabetes Treatments Semaglutide GLP-1 vs. Ozempic vs. – Benefits of Ozempic Injections Near

Name: does ozempic work better than semaglutide Ozempic® Pen vs Other Type 2 Diabetes Treatments Semaglutide GLP-1 vs. Ozempic vs. – Benefits of Ozempic Injections Near
Brand: museeartisanaletruralclion.fr
SKU: 82002816897
Price: 23.08 USD
Availability: InStock
Rating: 4.5625 (5 reviews)

SKU: 82002816897

4.6

USD23.08 USD64.08

Pay in 4 interest-free payments of $5.77 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 23 - Aug 28

Description

Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Granted Links 238000000855 fermentation Methods 0.000 title claims abstract description 109 230000004151 fermentation Effects 0.000 title claims abstract description 109 108010060325 semaglutide Proteins 0.000 title claims abstract description 32 DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 title claims abstract description 31 229950011186 semaglutide Drugs 0.000 title claims abstract description 31 239000002243 precursor Substances 0.000 title claims abstract description 16 238000000034 method Methods 0.000 title claims description 35 239000001963 growth medium Substances 0.000 claims abstract description 24 241000588724 Escherichia coli Species 0.000 claims abstract description 19 238000004519 manufacturing process Methods 0.000 claims abstract description 4 230000004913 activation Effects 0.000 claims description 34 239000002609 medium Substances 0.000 claims description 34 238000011218 seed culture Methods 0.000 claims description 22 230000001954 sterilising effect Effects 0.000 claims description 21 229940041514 candida albicans extract Drugs 0.000 claims description 18 230000006698 induction Effects 0.000 claims description 18 239000012138 yeast extract Substances 0.000 claims description 18 239000000843 powder Substances 0.000 claims description 16 239000013604 expression vector Substances 0.000 claims description 15 VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 14 WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 14 NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 14 235000011114 ammonium hydroxide Nutrition 0.000 claims description 14 239000008103 glucose Substances 0.000 claims description 14 108090000623 proteins and genes Proteins 0.000 claims description 14 238000004659 sterilization and disinfection Methods 0.000 claims description 14 CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 12 QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12 230000012010 growth Effects 0.000 claims description 12 229910052760 oxygen Inorganic materials 0.000 claims description 12 239000001301 oxygen Substances 0.000 claims description 12 JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 claims description 11 238000002360 preparation method Methods 0.000 claims description 11 FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10 238000003259 recombinant expression Methods 0.000 claims description 10 SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 claims description 9 230000001502 supplementing effect Effects 0.000 claims description 8 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 7 239000012378 ammonium molybdate tetrahydrate Substances 0.000 claims description 7 FIXLYHHVMHXSCP-UHFFFAOYSA-H azane;dihydroxy(dioxo)molybdenum;trioxomolybdenum;tetrahydrate Chemical compound N.N.N.N.N.N.O.O.O.O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O[Mo](O)(=O)=O.O[Mo](O)(=O)=O.O[Mo](O)(=O)=O FIXLYHHVMHXSCP-UHFFFAOYSA-H 0.000 claims description 7 BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 7 ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 claims description 7 108090000765 processed proteins & peptides Proteins 0.000 claims description 7 RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 claims description 7 UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6 YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 6 BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 6 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 6 235000011130 ammonium sulphate Nutrition 0.000 claims description 6 229960002303 citric acid monohydrate Drugs 0.000 claims description 6 238000003776 cleavage reaction Methods 0.000 claims description 6 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 6 235000019341 magnesium sulphate Nutrition 0.000 claims description 6 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 6 235000019796 monopotassium phosphate Nutrition 0.000 claims description 6 229920001184 polypeptide Polymers 0.000 claims description 6 102000004196 processed proteins & peptides Human genes 0.000 claims description 6 230000007017 scission Effects 0.000 claims description 6 239000011780 sodium chloride Substances 0.000 claims description 5 239000012137 tryptone Substances 0.000 claims description 5 238000001976 enzyme digestion Methods 0.000 claims description 4 230000004927 fusion Effects 0.000 claims description 4 XNCMOUSLNOHBKY-UHFFFAOYSA-H iron(3+);trisulfate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O XNCMOUSLNOHBKY-UHFFFAOYSA-H 0.000 claims description 4 GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 4 LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4 239000008213 purified water Substances 0.000 claims description 4 XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4 108020004705 Codon Proteins 0.000 claims description 3 238000010367 cloning Methods 0.000 claims description 3 238000010276 construction Methods 0.000 claims description 3 238000012216 screening Methods 0.000 claims description 3 230000035939 shock Effects 0.000 claims description 3 230000002194 synthesizing effect Effects 0.000 claims description 3 230000001131 transforming effect Effects 0.000 claims description 3 102000004190 Enzymes Human genes 0.000 claims description 2 108090000790 Enzymes Proteins 0.000 claims description 2 230000003213 activating effect Effects 0.000 claims description 2 238000005520 cutting process Methods 0.000 claims description 2 238000002156 mixing Methods 0.000 claims description 2 PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2 238000001816 cooling Methods 0.000 claims 1 241000894006 Bacteria Species 0.000 abstract description 38 239000002028 Biomass Substances 0.000 abstract description 3 230000000694 effects Effects 0.000 abstract description 2 210000003000 inclusion body Anatomy 0.000 abstract 1 229910001425 magnesium ion Inorganic materials 0.000 abstract 1 239000000203 mixture Substances 0.000 description 14 230000001276 controlling effect Effects 0.000 description 12 206010012601 diabetes mellitus Diseases 0.000 description 8 239000013589 supplement Substances 0.000 description 6 239000012526 feed medium Substances 0.000 description 5 239000011777 magnesium Substances 0.000 description 5 MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4 DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 4 238000012258 culturing Methods 0.000 description 4 239000000463 material Substances 0.000 description 4 102000004169 proteins and genes Human genes 0.000 description 4 108010016626 Dipeptides Proteins 0.000 description 3 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 3 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 3 PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3 239000004472 Lysine Substances 0.000 description 3 KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3 241001052560 Thallis Species 0.000 description 3 235000001014 amino acid Nutrition 0.000 description 3 150000001413 amino acids Chemical group 0.000 description 3 239000003814 drug Substances 0.000 description 3 238000001914 filtration Methods 0.000 description 3 238000009472 formulation Methods 0.000 description 3 230000005526 G1 to G0 transition Effects 0.000 description 2 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 2 238000002835 absorbance Methods 0.000 description 2 239000008280 blood Substances 0.000 description 2 210000004369 blood Anatomy 0.000 description 2 238000001514 detection method Methods 0.000 description 2 229940079593 drug Drugs 0.000 description 2 239000012634 fragment Substances 0.000 description 2 230000002218 hypoglycaemic effect Effects 0.000 description 2 239000000411 inducer Substances 0.000 description 2 NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2 244000005700 microbiome Species 0.000 description 2 238000002731 protein assay Methods 0.000 description 2 238000005070 sampling Methods 0.000 description 2 125000006850 spacer group Chemical group 0.000 description 2 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2 QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1 206010067484 Adverse reaction Diseases 0.000 description 1 102000009027 Albumins Human genes 0.000 description 1 108010088751 Albumins Proteins 0.000 description 1 239000004475 Arginine Substances 0.000 description 1 208000017667 Chronic Disease Diseases 0.000 description 1 QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1 108010011459 Exenatide Proteins 0.000 description 1 HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1 206010018429 Glucose tolerance impaired Diseases 0.000 description 1 101000788682 Homo sapiens GATA-type zinc finger protein 1 Proteins 0.000 description 1 101500028773 Homo sapiens Glucagon-like peptide 1(7-37) Proteins 0.000 description 1 208000013016 Hypoglycemia Diseases 0.000 description 1 102000004877 Insulin Human genes 0.000 description 1 108090001061 Insulin Proteins 0.000 description 1 QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1 108010019598 Liraglutide Proteins 0.000 description 1 YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1 208000008589 Obesity Diseases 0.000 description 1 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1 230000006838 adverse reaction Effects 0.000 description 1 235000004279 alanine Nutrition 0.000 description 1 229960004733 albiglutide Drugs 0.000 description 1 OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 1 230000003698 anagen phase Effects 0.000 description 1 238000004458 analytical method Methods 0.000 description 1 ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1 229960000074 biopharmaceutical Drugs 0.000 description 1 230000015572 biosynthetic process Effects 0.000 description 1 230000015556 catabolic process Effects 0.000 description 1 230000001684 chronic effect Effects 0.000 description 1 238000010835 comparative analysis Methods 0.000 description 1 230000007812 deficiency Effects 0.000 description 1 238000006731 degradation reaction Methods 0.000 description 1 230000001419 dependent effect Effects 0.000 description 1 230000018109 developmental process Effects 0.000 description 1 235000005911 diet Nutrition 0.000 description 1 230000000378 dietary effect Effects 0.000 description 1 201000010099 disease Diseases 0.000 description 1 208000016097 disease of metabolism Diseases 0.000 description 1 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1 238000011143 downstream manufacturing Methods 0.000 description 1 229960005175 dulaglutide Drugs 0.000 description 1 108010005794 dulaglutide Proteins 0.000 description 1 239000000839 emulsion Substances 0.000 description 1 238000005516 engineering process Methods 0.000 description 1 230000007613 environmental effect Effects 0.000 description 1 229960001519 exenatide Drugs 0.000 description 1 230000002068 genetic effect Effects 0.000 description 1 201000001421 hyperglycemia Diseases 0.000 description 1 238000001727 in vivo Methods 0.000 description 1 229940125396 insulin Drugs 0.000 description 1 230000003914 insulin secretion Effects 0.000 description 1 230000003993 interaction Effects 0.000 description 1 238000009630 liquid culture Methods 0.000 description 1 229960002701 liraglutide Drugs 0.000 description 1 230000007774 longterm Effects 0.000 description 1 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1 208000030159 metabolic disease Diseases 0.000 description 1 230000000813 microbial effect Effects 0.000 description 1 235000020824 obesity Nutrition 0.000 description 1 238000001742 protein purification Methods 0.000 description 1 238000000746 purification Methods 0.000 description 1 108700027806 rGLP-1 Proteins 0.000 description 1 239000002994 raw material Substances 0.000 description 1 230000001105 regulatory effect Effects 0.000 description 1 230000028327 secretion Effects 0.000 description 1 238000000926 separation method Methods 0.000 description 1 238000012163 sequencing technique Methods 0.000 description 1 238000003786 synthesis reaction Methods 0.000 description 1 TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1 230000003442 weekly effect Effects 0.000 description 1 230000004580 weight loss Effects 0.000 description 1 Images Classifications CCHEMISTRY